WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522486
Description: DS-1558 is a potent and orally available GPR40 agonist.DS-1558 was found to have potent glucose lowering effects during an oral glucose tolerance test in ZDF rats. DS-1558 significantly and dose-dependently improved hyperglycemia and increased insulin secretion during the oral glucose tolerance test in Zucker fatty rats, the model of insulin resistance and glucose intolerance. DS-1558 not only increased the glucose-stimulated insulin secretion by GLP-1 but also potentiated the maximum insulinogenic effects of GLP-1 after an intravenous glucose injection in normal Sprague Dawley rats.
MedKoo Cat#: 522486
Chemical Formula: C21H21F3O4
Exact Mass: 394.13919
Molecular Weight: 394.39021
Elemental Analysis: C, 63.95; H, 5.37; F, 14.45; O, 16.23
DS-1558 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: DS-1558; DS 1558; DS1558.
IUPAC/Chemical Name: (S)-3-ethoxy-3-(4-(((R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)propanoic acid
InChi Key: YHLQVQKZDZYMIP-MOPGFXCFSA-N
InChi Code: InChI=1S/C21H21F3O4/c1-2-27-19(12-20(25)26)13-6-8-14(9-7-13)28-18-11-10-15-16(18)4-3-5-17(15)21(22,23)24/h3-9,18-19H,2,10-12H2,1H3,(H,25,26)/t18-,19+/m1/s1
SMILES Code: FC(F)(F)C1=CC=CC2=C1CC[C@H]2OC(C=C3)=CC=C3[C@H](CC(O)=O)OCC
The following data is based on the product molecular weight 394.39021 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Takano R, Yoshida M, Inoue M, Honda T, Nakashima R, Matsumoto K, Yano T, Ogata
T, Watanabe N, Hirouchi M, Kimura T, Toda N. Optimization of
3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558.
Bioorg Med Chem. 2015 Sep 1;23(17):5546-65. doi: 10.1016/j.bmc.2015.07.028. Epub
2015 Jul 23. PubMed PMID: 26234904.
2: Takano R, Yoshida M, Inoue M, Honda T, Nakashima R, Matsumoto K, Yano T, Ogata
T, Watanabe N, Hirouchi M, Yoneyama T, Ito S, Toda N. Discovery of DS-1558: A
Potent and Orally Bioavailable GPR40 Agonist. ACS Med Chem Lett. 2015 Jan
13;6(3):266-70. doi: 10.1021/ml500391n. eCollection 2015 Mar 12. PubMed PMID:
25815144; PubMed Central PMCID: PMC4360146.
3: Nakashima R, Yano T, Ogawa J, Tanaka N, Toda N, Yoshida M, Takano R, Inoue M,
Honda T, Kume S, Matsumoto K. Potentiation of insulin secretion and improvement
of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist
DS-1558 with glucagon-like peptide-1 receptor agonists. Eur J Pharmacol. 2014 Aug
15;737:194-201. doi: 10.1016/j.ejphar.2014.05.014. Epub 2014 May 22. PubMed PMID: